The Effect of Erythropoietin on Alveolar Fluid Clearance in Patients With Acute Respiratory Distress Syndrome
Recruiting now · Not applicable
Conditions studied: Acute Respiratory Distress Syndrome
In brief
Acute respiratory distress syndrome (ARDS) is a common acute and critical disease in clinic. The clinical mortality is as high as 30%-40%. At present, there is no specific treatment. Erythropoietin (EPO), also known as erythrocyte- stimulating factor, erythropoietin, has a certain amount in normal human body, mainly synthesized by liver in infants and kidneys in adults, which can stimulate erythropoiesis. In recent years, more and more studies have shown that high-dose exogenous EPO administration has benefit effects on multi-organ protection. Therefore, we designed this prospective, double-blind, placebo-controlled trial for defecting EPO on the alveolar fluid clearance of ARDS. The study mainly answers the following questions: Does human erythropoietin accelerate the resolution of alveolar edema in ARDS? Is there any effect on hospital survival? The study will draw conclusions by comparing the control group with the experimental group.
Key facts
- Study ID
- NCT05857891
- Run by
- Second Affiliated Hospital of Wenzhou Medical University
- People needed
- 40
- Starts
- 2023-05-20
- Expected to finish
- 2027-03-31
- Last updated by the study team
- 2023-05-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age≥18 years;
- Meeting diagnostic criteria for sepsis 3.0;
- Tracheal intubation and mechanical ventilation;
- Meeting the diagnostic criteria of ARDS Berlin;
- Willing to accept treatment and sign an informed consent form;
You may not qualify if…
- Age <18 years;
- Pregnancy or lactation;
- Patients with malignant tumors;
- Recombinant human erythropoietin (rhEPO) allergic patients;
- Hemoglobin (Hb) ≥120g/L;
- have recently taken rhEPO (within 3 months) or participated in other clinical trials;
- History of thromboembolic disease (pulmonary embolism, heart attack, cerebral infarction, arteriovenous thrombosis);
- Inability or unwillingness to provide informed consent or to comply with the requirements of the study;
Where it is running
- SAHWenzhouMU — Wenzhou, Zhejiang, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.